Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Proforma Information (Details)

v3.24.1.1.u2
Business combinations - Proforma Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Jun. 01, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Merger with TCR2 Therapeutics Inc.        
Share-based compensation expense   $ 3,102,000 $ 1,676,000  
TCR2 Therapeutics        
Merger with TCR2 Therapeutics Inc.        
Revenue   47,601    
Net loss   (31,325)    
Acquisition-related costs incurred by TCR2   3,700,000    
Gain on bargain purchase $ 22,049,000      
Acquisition-related costs   $ 4,073,000 3,800,000 $ 7,346,000
Share-based compensation expense     $ 600,000